USRE30971E - Compositions containing platinum - Google Patents

Compositions containing platinum Download PDF

Info

Publication number
USRE30971E
USRE30971E US06/119,656 US11965680A USRE30971E US RE30971 E USRE30971 E US RE30971E US 11965680 A US11965680 A US 11965680A US RE30971 E USRE30971 E US RE30971E
Authority
US
United States
Prior art keywords
platinum
groups
compound according
same
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/119,656
Inventor
Martin L. Tobe
Abdul R. Khokhar
Peter D. M. Braddock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rustenburg Platinum Mines Ltd
Original Assignee
Rustenburg Platinum Mines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rustenburg Platinum Mines Ltd filed Critical Rustenburg Platinum Mines Ltd
Application granted granted Critical
Publication of USRE30971E publication Critical patent/USRE30971E/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to new compositions of matter containing platinum.
  • a composition of matter comprises a co-ordination compound of platinum having the structure: ##STR2## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide or pseudohalide such as cyanate, thiocyanate and azide and A and B are the same or different branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms.
  • a co-ordination compound of platinum having the structure: ##STR3## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide pseudohalide such as cyanide, cyanate, thiocyanate, or azide or other similar groups and A and B are the same or different branched chain aliphatic amine groups or C-substituted branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms each having the general formula
  • n may vary from 3 to 9 and in which all of the R groups are either the same or different and are preferably all hydrogen but may be selected from the group consisting of hydrogen, alkyl, aryl, alkaryl, aralkyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, sulphonic acid, sulphonic acid salt, carboxylic acid, carboxylic acid salt, and substituted alkyl, aryl, alkaryl and aralkyl groups.
  • the platinum is preferably present as Pt 4+ , thus producing a neutral complex with two hydroxyl and two halide ligands.
  • R groups other than hydrogen are not normally preferred, they may be used and may comprise lower alkyl such as methyl or ethyl or a solubilizing group such as a sulphonic acid group.
  • Solubilizing groups as substituents such as carboxylic acid, sulphonic acid, carboxylic acid salt, sulphonic acid salt, e.g. the sodium, potassium or lithium salts are sometimes appropriate when the clinical conditions require high solubility.
  • halogenoid is used to mean halide (chloride, bromide, iodide or fluoride) or pseudohalide such as cyanide, cyanate, thiocyanate or azide.
  • Suitable branched chain amine compounds which may be used for groups A and B are isopropylamine, isobutylamine, isoamylamine and 2-aminohexane.
  • branched chain amines which may be used as ligands A and B are:
  • the complexes are prepared by the general method of heating a slurry of the respective cis-diaminedichloroplatinum (II) complex with hydrogen peroxide solution as exemplified below.
  • Recrystallised cis- [Pt(i-C 3 H 7 NH 2 ) 2 Cl 2 ] (26.8 g) was slurried in hot water (50 ml) and aqueous hydrogen peroxide (40% v/v, 100 ml) was added with stirring. The slurry was boiled for 0.5 hours until yellow in colour, chilled, filtered and the residue washed with water, etharal and air dried. The crude product (20 g) was recrystallised from water (285 ml) with hydrogen peroxide solution (15 ml) and dried in vacuo at 100° C. for four hours.
  • Recrystallised cis- [Pt(C 7 H 15 NH 2 ) 2 Cl 2 ] (15 g) was slurried in warm water (31 ml) and hydrogen peroxide solution (40% v/v,60 ml) was added with stirring. The slurry was boiled for ten minutes, chilled, filtered and the orange product washed with water and dried in vacuo.
  • Platinum (IV) complexes are more soluble than Platinum (IV) complexes are more soluble than platinum (II) complexes and, after solubilizing Pt(IV) may be used in the form of Pt(II).
  • the branched chain amine complexes of Pt(IV) are also useful in catalyst preparation by impregnating supports with an aqueous solution of the complex. Alternatively, the solution may be based upon an organic medium.
  • the complexes of the invention may also be used as catalysts in the hydrosilation of organic compounds so as to introduce a silica radical into an organic compound and as synthetic intermediate compounds.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a compound of platinum having the structure: ##STR1## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide or pseudohalide such as cyanate, thiocyanate and azide or other similar groups, and A and B are the same or different branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms.

Description

This invention relates to new compositions of matter containing platinum.
According to one aspect of the present invention a composition of matter comprises a co-ordination compound of platinum having the structure: ##STR2## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide or pseudohalide such as cyanate, thiocyanate and azide and A and B are the same or different branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms.
According to a second aspect of the present invention there is provided a co-ordination compound of platinum having the structure: ##STR3## in which X and Y are halogenoid groups which are the same or different and are preferably both chloride but may be other halide pseudohalide such as cyanide, cyanate, thiocyanate, or azide or other similar groups and A and B are the same or different branched chain aliphatic amine groups or C-substituted branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms each having the general formula
C.sub.n R.sub.2n+1 NH.sub.2
in which n may vary from 3 to 9 and in which all of the R groups are either the same or different and are preferably all hydrogen but may be selected from the group consisting of hydrogen, alkyl, aryl, alkaryl, aralkyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, sulphonic acid, sulphonic acid salt, carboxylic acid, carboxylic acid salt, and substituted alkyl, aryl, alkaryl and aralkyl groups.
The platinum is preferably present as Pt4+, thus producing a neutral complex with two hydroxyl and two halide ligands.
Although R groups other than hydrogen are not normally preferred, they may be used and may comprise lower alkyl such as methyl or ethyl or a solubilizing group such as a sulphonic acid group. Solubilizing groups as substituents such as carboxylic acid, sulphonic acid, carboxylic acid salt, sulphonic acid salt, e.g. the sodium, potassium or lithium salts are sometimes appropriate when the clinical conditions require high solubility.
Throughout the specification and claims, the term "halogenoid" is used to mean halide (chloride, bromide, iodide or fluoride) or pseudohalide such as cyanide, cyanate, thiocyanate or azide.
Suitable branched chain amine compounds which may be used for groups A and B are isopropylamine, isobutylamine, isoamylamine and 2-aminohexane.
Results obtained using trans di-hydroxo complexes of Pt(IV) where in the above formula X and Y are both chloride and A and B are the same stated branched chain amine are as follows:
______________________________________                                    
                mgm./Kgm  Therapeutic                                     
Tumour   A and B      ID.sub.90                                           
                              LD.sub.50                                   
                                    Index (II)                            
______________________________________                                    
ADJ/PC6  exo 2 amino nor                                                  
                      40.5    660   16.3                                  
         bornane                                                          
         ISO propylamine                                                  
                      7.5     90    12.0                                  
         (oil)                                                            
         (water)      4.2     54    12.9                                  
         ISO Butylamine                                                   
                      19.5    410   21                                    
         ISO pentylamine                                                  
                      112     800   7.1                                   
         (amylamine)  19.0    20    37.9                                  
______________________________________                                    
                      ED.sub.90                                           
                              LD.sub.50                                   
                                    TI                                    
______________________________________                                    
Walker   ISO propylamine                                                  
         (oil)        17      45    2.6                                   
         (water)      16      56    3.5                                   
______________________________________
These results were obtained using the standard test protocol for the ADJ/PC6 and Walker tumours on Balb-c white mice.
These series of results obtained using the standard test protocol for the P 388 (ascitic) lymphocytic leukaemia using the isopropylamine complex are as follows:
______________________________________                                    
                                        % age                             
      Control  Animal                   Increase                          
Dose  Body     weight    Tumour  Control                                  
                                        in life                           
mgm/  weight   difference                                                 
                         evaluation                                       
                                 (Days) span                              
Kgm   change   (T - C)   Test (days)                                      
                                 (C)    (T/C)                             
______________________________________                                    
200   -1.4     -4.6      6.2     15.5                                     
100   -1.4     -4.0      6.4     15.5                                     
50.0  -1.4     -3.6      24.0    15.5   154                               
25.0  -1.4     -1.6      23.3    15.5   150                               
12.5  -1.4     -1.8      21.3    15.5   137                               
200   1.0      -1.0      4.19    11.8                                     
100   1.0      -6.4      6.1     11.8                                     
50.0  1.0      -6.5      8.0     11.8                                     
25.0  1.0      -5.7      15.0    11.8   127                               
12.5  1.0      -4.2      21.8    11.8   184                               
200   1.0      -1.0      3.0     11.8                                     
100   1.0      -6.5      6.8     11.8                                     
50.0  1.0      -5.2      18.0    11.8   152                               
25.0  1.0      -4.0      16.1    11.8   136                               
12.5  1.0      -2.5      15.3    11.8   129                               
______________________________________
Other branched chain amines which may be used as ligands A and B are:
2 amino 5 methylhexane
2 amine 4 methylhexane
2 amino heptane
tert. butylamine
Methods of Preparation
Preferred methods of preparation of trans dihydroxo cis dichloro diamine Pt (IV) complexes (i.e. where A+B in the above defined structure are as follows:
The complexes are prepared by the general method of heating a slurry of the respective cis-diaminedichloroplatinum (II) complex with hydrogen peroxide solution as exemplified below.
Preparation of cis-Dichloro-trans-dihydroxybis(Isopropylamine) platinum IV hydrate (1/1)
Recrystallised cis- [Pt(i-C3 H7 NH2)2 Cl2 ] (26.8 g) was slurried in hot water (50 ml) and aqueous hydrogen peroxide (40% v/v, 100 ml) was added with stirring. The slurry was boiled for 0.5 hours until yellow in colour, chilled, filtered and the residue washed with water, etharal and air dried. The crude product (20 g) was recrystallised from water (285 ml) with hydrogen peroxide solution (15 ml) and dried in vacuo at 100° C. for four hours.
Yield 10.5 g. 35%
______________________________________                                    
Elemental analysis                                                        
            C        H       N     O     Cl                               
______________________________________                                    
Calculated %                                                              
            16.5     5.1     6.4   11.-  16.3                             
Found %     16.6     4.8     6.4   11.7  16.1                             
______________________________________
Infra-red spectrum
The hydroxyl stretching absorption (vo --H) occurs at 3515 m cm-1
Preparation of cis-bis(2-amino-5-methylhexane)dichloro-trans dihydroxy platinum (IV)
Recrystallised cis- [Pt(C7 H15 NH2)2 Cl2 ] (15 g) was slurried in warm water (31 ml) and hydrogen peroxide solution (40% v/v,60 ml) was added with stirring. The slurry was boiled for ten minutes, chilled, filtered and the orange product washed with water and dried in vacuo.
Yield 7.4 g. 46%
______________________________________                                    
Elemental analysis                                                        
            C        H       N     O     Cl                               
______________________________________                                    
Calculated %                                                              
            31.7     6.8     5.3   6.0   13.4                             
Found %     32.1     6.7     5.5   6.2   13.6                             
______________________________________
Infra-red Spectrum
The hydroxyl stretching absorption (vo --H) occurs at 3340 mg cm-1.
Platinum (IV) complexes are more soluble than Platinum (IV) complexes are more soluble than platinum (II) complexes and, after solubilizing Pt(IV) may be used in the form of Pt(II). The branched chain amine complexes of Pt(IV) are also useful in catalyst preparation by impregnating supports with an aqueous solution of the complex. Alternatively, the solution may be based upon an organic medium. The complexes of the invention may also be used as catalysts in the hydrosilation of organic compounds so as to introduce a silica radical into an organic compound and as synthetic intermediate compounds.

Claims (7)

What is claimed is:
1. A co-ordination compound of platinum having the structure: ##STR4## in which X and Y are halogen and A and B are the same or different branched chain aliphatic amine groups or C-substituted branched chain aliphatic amine groups co-ordinated to the Pt through their N atoms each having the general formula
C.sub.n R.sub.2n+1 NH.sub.2
in which n may vary from 3 to 9 and in which all of the R groups are the same or different and are selected from the group consisting of hydrogen, alkyl, aryl, alkaryl, aralkyl, halogen, pseudohalogen, hydroxy, carbonyl, formyl, nitro, amido, amino, sulphonic acid, sulphonic acid salt, carboxylic acid and carboxylic acid salt.
2. A compound according to claim 1 in which X and Y are both chlorine and R is hydrogen.
3. A compound according to claim 1 wherein the platinum is present as Pt4+.
4. A compound according to claim 1 wherein the R groups are the same or different lower alkyl.
5. A compound according to claim 1 wherein A and B are isopropylamine, isobutylamine, isoamylamine and 2-aminohexane.
6. A composition comprising a co-ordination compound of platinum having the structures: ##STR5## in which X and Y are halogen and A and B are exo 2 amino norbornane. .Iadd.
7. The compound cis-dichloro-trans-dihydroxybis (isopropylamine) platinum IV hydrate. .Iaddend..Iadd. 8. A compound according to claim 1 wherein X and Y are both chlorine and A and B are both isopropylamine. .Iaddend.
US06/119,656 1976-02-26 1980-02-20 Compositions containing platinum Expired - Lifetime USRE30971E (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7650/76A GB1578323A (en) 1976-02-26 1976-02-26 Compositions containing platinum
GB7650/76 1976-02-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US05/770,313 Reissue US4119654A (en) 1976-02-26 1977-02-22 Compositions containing platinum

Publications (1)

Publication Number Publication Date
USRE30971E true USRE30971E (en) 1982-06-15

Family

ID=9837176

Family Applications (2)

Application Number Title Priority Date Filing Date
US05/770,313 Ceased US4119654A (en) 1976-02-26 1977-02-22 Compositions containing platinum
US06/119,656 Expired - Lifetime USRE30971E (en) 1976-02-26 1980-02-20 Compositions containing platinum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US05/770,313 Ceased US4119654A (en) 1976-02-26 1977-02-22 Compositions containing platinum

Country Status (10)

Country Link
US (2) US4119654A (en)
JP (1) JPS52122323A (en)
BE (1) BE851811A (en)
CA (1) CA1100983A (en)
CH (1) CH629744A5 (en)
DE (1) DE2707934A1 (en)
FR (1) FR2342299A1 (en)
GB (1) GB1578323A (en)
NL (1) NL187268C (en)
ZA (1) ZA771163B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658047A (en) 1985-09-27 1987-04-14 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing 1,2-diaminocyclohexane tetrachloro platinum (IV) isomers

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182724A (en) * 1976-04-06 1980-01-08 Rustenburg Platinum Mines Limited Compositions containing platinum
SE7903359L (en) * 1978-04-20 1979-10-21 Johnson Matthey Co Ltd COMPOSITIONS CONTAINING PLATINUM
SE7903361L (en) * 1978-04-20 1979-10-21 Johnson Matthey Co Ltd COMPOSITIONS CONTAINING PLATINUM
US4329299A (en) * 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
NL181434C (en) * 1980-01-03 1987-08-17 Tno PLATINUM (IV) DIAMINE COMPLEXES, AND THEIR PREPARATION AND APPLICATION.
US4376782A (en) * 1980-05-21 1983-03-15 Research Corporation Complexes of square planar platinum II compounds and N-methyl glucamine
GR75317B (en) * 1980-09-03 1984-07-13 Johnson Matthey Plc
ZA815852B (en) * 1980-09-03 1982-08-25 Johnson Matthey Plc Co-ordination compound of platinum
NL8101026A (en) * 1981-03-03 1982-10-01 Tno PLATINADIAMINE COMPLEXES, A METHOD FOR PREPARING THE SAME, A METHOD FOR PREPARING A MEDICINAL PRODUCT USING SUCH PLATINADIAMINE COMPLEX FOR THE TREATMENT OF CANCER AND CONTAINED IN SUCH FORM.
JPS5896024A (en) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル Platinum toxicity detoxicant
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
US4617189A (en) * 1983-04-14 1986-10-14 Stockel Richard F Use of selenium-containing compounds for negating the toxic effects of platinum compounds used in chemotherapy, and a novel selenium-containing platinum compound and use thereof as an anti-cancer medicine
US4670458A (en) * 1986-01-31 1987-06-02 American Cyanamid Company Hydroxylated 1,2-diaminocyclohexane platinum complexes
JPH01168146A (en) * 1987-12-24 1989-07-03 Canon Inc telephone
FI905018A7 (en) * 1989-10-17 1991-04-18 Bristol Myers Squibb Co Water and solvent soluble axial hydroxy and mono- and di-carboxylic acid derivatives with high antitumor activity
US5196555A (en) * 1989-10-17 1993-03-23 Bristol-Myers Squibb Company Water and solvent soluble axial hydroxy and mono- and di- carboxylic acid derivatives having high tumor activity
ES2181602B1 (en) * 2001-07-30 2004-06-16 Universidad Autonoma De Madrid "PT (IV) COMPLEX WITH ANTHINEOPLASTIC ACTIVITY: TRANS- (PTCL2 (OH) 2 (DIMETHYLAMINE) (ISOPROPYLAMINE)) APPLICABLE AS ANTITUMORAL.
GB0120618D0 (en) * 2001-08-24 2001-10-17 Univerity Court Of The Univers Photoreactive compounds and compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892790A (en) * 1972-04-10 1975-07-01 Rustenburg Platinum Mines Ltd Compositions containing platinum
US3904663A (en) * 1972-04-10 1975-09-09 Rustenburg Platinum Mines Ltd Compositions containing platinum

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892790A (en) * 1972-04-10 1975-07-01 Rustenburg Platinum Mines Ltd Compositions containing platinum
US3904663A (en) * 1972-04-10 1975-09-09 Rustenburg Platinum Mines Ltd Compositions containing platinum
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"American Druggist, Pharmaceutical and Medical Science," pp. 33 & 34, (1969). *
Belluco, Organometallic and Coordination Chemistry of Platinum, Academic Press, N.Y., pp. 93-95, 547-549, (1974). *
Braddock et al., Chem. Bio. Interactions, vol. 11, No. 3, pp. 146-149, (1975). *
Cleare et al., Bioinorganic Chemistry, vol. 2, pp. 187-210, (1973). *
Connors et al., Chem. Biol. Interaction, vol. 5, pp. 415-424, (1972). *
Gale et al., Research Communications in Chemical Pathology and Pharmocology, vol. 7, pp. 529-538, (1974). *
Tobe et al., J. of Clin. Hematology & Oncology, vol. 7, No. 1, pp. 129-131 & 133, (1977). *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658047A (en) 1985-09-27 1987-04-14 The United States Of America As Represented By The Department Of Health And Human Services Method of preparing 1,2-diaminocyclohexane tetrachloro platinum (IV) isomers

Also Published As

Publication number Publication date
NL187268C (en) 1991-08-01
NL7701909A (en) 1977-08-30
US4119654A (en) 1978-10-10
DE2707934A1 (en) 1977-09-01
JPS61354B2 (en) 1986-01-08
FR2342299B1 (en) 1980-06-13
CA1100983A (en) 1981-05-12
NL187268B (en) 1991-03-01
JPS52122323A (en) 1977-10-14
BE851811A (en) 1977-06-16
GB1578323A (en) 1980-11-05
ZA771163B (en) 1978-01-25
CH629744A5 (en) 1982-05-14
DE2707934C2 (en) 1989-02-02
FR2342299A1 (en) 1977-09-23

Similar Documents

Publication Publication Date Title
USRE30971E (en) Compositions containing platinum
US3892790A (en) Compositions containing platinum
US4119653A (en) Co-ordination compounds of platinum
US4329299A (en) Composition of matter containing platinum
US4115418A (en) 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4140707A (en) Malonato platinum anti-tumor compounds
US4225529A (en) Compositions containing platinum
Hoeschele et al. Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum (II) chelate complexes incorporating the cis-1, 4-diaminocyclohexane ligand in a unique locked boat conformation
US5426203A (en) Platinum complexes of malonic acid derivatives and process for the preparation thereof
CA1134378A (en) Cis-platinum(ii) amine lactate complexes
CS239911B2 (en) Processing of complexed diamino platinum
US4607114A (en) Novel platinum complexes
US4230631A (en) Platinum coordination compounds
JPH04327596A (en) New trans-pt(iv) compound
US4902797A (en) Ammine-alicyclic amine-platinum complexes and antitumor agents
US4234500A (en) Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes
US4657927A (en) Malonato platinum compounds
US4182724A (en) Compositions containing platinum
Frink et al. Synthesis and excited-state properties of rhodium (III) terpyridine complexes
US4291027A (en) Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes
US4739087A (en) Antineoplastic platinum complexes
US4175133A (en) 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia
GB2055377A (en) Cis-platinum(II) amine ascorbate complexes
US4720504A (en) Use of bis-platinum complexes as antitumor agents
US4921973A (en) Platinum complexes and the like